Harpreet Singh: Exciting news in colorectal cancer treatment

Harpreet Singh, Chief Medical Officer at Precision For Medicine, shared a post on LinkedIn:

“Exciting news in colorectal cancer treatment! The FDA has granted accelerated approval for adagrasib + cetuximab, targeting KRAS G12C mutations.

Key takeaways from my latest video:

• First KRAS G12C targeting drug approved for colorectal cancer
• 34% overall response rate in the KRYSTAL-1 trial
• Addresses ~4% of colorectal cancer patients with this specific mutation
• KRAS was previously considered ‘undruggable’ in this cancer type
• This approval marks a significant step forward in precision medicine for colorectal cancer.

The KRYSTAL-10 confirmatory trial is now fully enrolled, and its results could potentially convert this to a full FDA approval.

What are your thoughts on targeting previously ‘undruggable’ mutations? What impact do you see long-term?

Follow for more.”

Proceed to the video attached to the post.
Source: Harpreet Singh/LinkedIn

More posts by Harpreet Singh in OncoDaily.